Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 12/20 | 0.74 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | F12 | P00748 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.44 |
| ▸ | LOX | P28300 | 3/20 | 0.44 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16246756 | 0.98 | ROCK1 (0.72) | ROCK1PLAUF12NCF1NOS3 | |
| SCHEMBL29481418 | 0.85 | ROCK1 (1.00) | ROCK1PLAUF12NCF1NOS3 | |
| SCHEMBL5735425 | 0.85 | ROCK1 (1.00) | ROCK1PLAUF12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL29481411 | 0.84 | ROCK1 (0.96) | ROCK1PLAUF12NCF1NOS3 | |
| SCHEMBL6982094 | 0.84 | ROCK1 (0.53) | ROCK1PLAUF12NCF1NOS3 | |
| SCHEMBL6983215 | 0.84 | PLAU (0.60) | ROCK1PLAUF12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL3759590 | 0.84 | ROCK1 (0.96) | ROCK1PLAUF12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL5731184 | 0.84 | ROCK1 (0.96) | ROCK1PLAUF12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL29508477 | 0.84 | ROCK1 (0.96) | ROCK1PLAUF12NCF1NOS3 | |
| SCHEMBL24358795 | 0.82 | ROCK1 (0.51) | ROCK1PLAUF12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20220298141-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4017849-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114286820-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| CN-105452240-B | Hete rocyclic derivatives | 卡尔维斯塔制药有限公司 | 2018-06-26 | — | — | CN | disclosed |
| EP-3305778-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-6642253-B2 | Thrombin inhibitors comprising an aminoisoquinoline group | AKZO NOBEL N. V. (NL) | 2003-11-04 | — | — | US | disclosed |
| CN-1441784-A | Thrombin inhibitors comprising aminoisoquinoline group | AKZO NOBEL NV (NL) | 2003-09-10 | — | — | CN | disclosed |
| US-20030166579-A1 | THROMBIN INHIBITORS COMPRISING AN AMINOISOQUINOLINE GROUP | N.V. ORGANON (NL) | 2003-09-04 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | ROCK1 3348/4885PLAU 2528/4885F12 170/4885 |
| US-20220298141-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | ROCK1 1964/4885PLAU 304/4885F12 702/4885 |
| US-20030166579-A1 | THROMBIN INHIBITORS COMPRISING AN AMINOISOQUINOLINE GROUP | F2, TFPI, SERPINC1 | ROCK1 346/4885PLAU 88/4885F12 21/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | ROCK1 1266/4885PLAU 171/4885F12 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.